@article {44691,
	title = {miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma},
	journal = {Journal of Translational Medicine},
	volume = {21},
	number = {1},
	year = {2023},
	note = {Papadimitriou, Maria-AlexandraSoureas, KonstantinosPapanota, Aristea-MariaTsiakanikas, PanagiotisAdamopoulos, Panagiotis GNtanasis-Stathopoulos, IoannisMalandrakis, PanagiotisGavriatopoulou, MariaSideris, Diamantis CKastritis, EfstathiosAvgeris, MargaritisDimopoulos, Meletios-AthanasiosTerpos, EvangelosScorilas, AndreasengEngland2023/04/07 06:00J Transl Med. 2023 Apr 6;21(1):245. doi: 10.1186/s12967-023-04034-5.},
	month = {Apr 6},
	pages = {245},
	abstract = {BACKGROUND: Despite significant advancements in multiple myeloma (MM) therapy, the highly heterogenous treatment response hinders reliable prognosis and tailored therapeutics. Herein, we have studied the clinical utility of miRNAs in ameliorating patients{\textquoteright} management. METHODS: miRNA-seq was performed in bone marrow CD138+ plasma cells (PCs) of 24 MM and smoldering MM (sMM) patients to analyze miRNAs profile. CD138+ and circulating miR-25 levels were quantified using in house RT-qPCR assays in our screening MM/sMM cohort (CD138+ plasma cells n = 167; subcohort of MM peripheral plasma samples n = 69). Two external datasets (Kryukov et al. cohort n = 149; MMRF CoMMpass study n = 760) served as institutional-independent validation cohorts. Patients{\textquoteright} mortality and disease progression were assessed as clinical endpoints. Internal validation was performed by bootstrap analysis. Clinical benefit was estimated by decision curve analysis. RESULTS: miRNA-seq highlighted miR-25 of CD138+ plasma cells to be upregulated in MM vs. sMM, R-ISS II/III vs. R-ISS I, and in progressed compared to progression-free patients. The analysis of our screening cohort highlighted that CD138+ miR-25 levels were correlated with short-term progression (HR = 2.729; p = 0.009) and poor survival (HR = 4.581; p = 0.004) of the patients; which was confirmed by Kryukov et al. cohort (HR = 1.878; p = 0.005) and MMRF CoMMpass study (HR = 1.414; p = 0.039) validation cohorts. Moreover, multivariate miR-25-fitted models contributed to superior risk-stratification and clinical benefit in MM prognostication. Finally, elevated miR-25 circulating levels were correlated with poor survival of MM patients (HR = 5.435; p = 0.021), serving as a potent non-invasive molecular prognostic tool. CONCLUSIONS: Our study identified miR-25 overexpression as a powerful independent predictor of poor treatment outcome and post-treatment progression, aiding towards modern non-invasive disease prognosis and personalized treatment decisions.},
	keywords = {*MicroRNAs/genetics, *Multiple Myeloma/genetics/therapy, CD138 + plasma cells, hematological malignancies, Humans, miRNA, miRNA-seq, non-coding RNAs, Prognosis, Small RNA-seq, Treatment Outcome},
	isbn = {1479-5876 (Electronic)1479-5876 (Linking)},
	author = {Papadimitriou, M. A. and Soureas, K. and Papanota, A. M. and Tsiakanikas, P. and Adamopoulos, P.G. and Ntanasis-Stathopoulos, I. and Malandrakis, P. and Gavriatopoulou, M. and Sideris, D. C. and Kastritis, E. and Avgeris, M. and Dimopoulos, M.A. and Terpos, E. and Scorilas, A.}
}
